ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes

Zhou, Jiandong; Liu, Xuejin; Chou, Oscar Hou-In; Li, Lifang; Lee, Sharen; Wong, Wing Tak; Zhang, Qingpeng; Chang, Carlin; Liu, Tong; Tse, Gary; Jing, Fengshi*; Cheung, Bernard Man Yung*kaili univ; univ hong kong; chinese univ hong kong; tianjin med univ
RHEUMATOLOGY2023-4-3DOI: 10.1093/rheumatology/keac509
12被引7阅读
引用收藏
分享

摘要

Background The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks. Methods This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 in Hong Kong. The study outcomes are new-onset gout and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I was performed. Univariable and multivariable Cox regression models were conducted. Competing risks models and multiple approaches based on the propensity score were applied. Results This study included 43 201 patients [median age: 63.23 years old (Interquartile range, IQR): 55.21-71.95, 53.74% males; SGLT2I group: n = 16 144; DPP4I group: n = 27 057] with a median follow-up of 5.59 years (IQR: 5.27-5.81 years) since initial drug exposure. The incidence rate of developing gout [Incidence rate (IR): 2.5; 95% CI: 2.2, 2.9] among SGLT2I users was significantly lower than DPP4I users (IR: 5.2; 95% CI: 4.8, 5.8). SGLT2I was associated with 51% lower risks of gout (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) and 51% lower risks of all-cause mortality (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory results. The results remained consistent on competing risk and other propensity score approaches. Conclusions SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use.

学科与关键词

关键词
SGLT2DPP4anti-diabetic drugsdiabetes mellitusmetabolic syndromegoutcrystalline arthropathymortalityretrospective studycohort study
相关
加载中…
  • Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study
    Chou, O. H., I; Liu, X.; Zhou, J.; Jing, F.; Li, L.; Lee, S.; Wong, W. T.; Zhang, Q.; Chang, C.; Liu, T.; Tse, G.; Cheung, B. M. Y.
  • Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
    Lee, Sharen; Zhou, Jiandong; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Jeevaratnam, Kamalan; King, Emma; Liu, Tong; Wong, Wing Tak; Chang, Carlin; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Tse, Gary*; Zhang, Qingpeng*Cardiovascular Drugs and Therapy, 2023, 37(3): 561-569.被引 18
  • Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study
    Chung, Cheuk To; Lakhani, Ishan; Chou, Oscar Hou In; Lee, Teddy Tai Loy; Dee, Christopher; Ng, Kendrick; Wong, Wing Tak; Liu, Tong; Lee, Sharen; Zhang, Qingpeng; Cheung, Bernard Man Yung; Tse, Gary*; Zhou, Jiandong*Cancer Medicine, 2023, 12(11): 12299-12315.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
RHEUMATOLOGY
发表日期
2023-04-03
卷期
第 62 卷, 第 4 期
页码
1501-1510
DOI
10.1093/rheumatology/keac509
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhou, Jiandong (第一作者)

  • L

    Liu, Xuejin

    kaili univ

查看全部 12 位作者收起作者
  • C

    Chou, Oscar Hou-In

    univ hong kong

  • L

    Li, Lifang

  • L

    Lee, Sharen

  • W

    Wong, Wing Tak

    chinese univ hong kong

  • Z

    Zhang, Qingpeng

  • C

    Chang, Carlin

  • L

    Liu, Tong

    tianjin med univ

  • T

    Tse, Gary

    tianjin med univ

  • J

    Jing, Fengshi (通讯)

  • C

    Cheung, Bernard Man Yung (通讯)

    univ hong kong

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417